Cigna Group 8-K/A, filed Jul 28, 2025
Cigna Group (CI)
8-K/A
2025-07-28
For: 2025-05-30
View Original
Added on
April 03, 2026
About this 8-K/A
Cigna Group filed this 8-K/A on July 28, 2025, reporting on events of May 30, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 30, 2025
(Exact name of registrant as specified in its charter)
|
|
|
|
| (State or other jurisdiction of incorporation) | (Commission File Number) |
(IRS Employer Identification No.)
|
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
(860 ) 226-6000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or
Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On June 2, 2025, The Cigna Group (the “Company”) filed a Current Report on Form 8-K announcing the action by the Company’s Board of Directors (the “Board”) on May 30, 2025
to appoint Michael J. Hennigan as an independent member of the Board, effective June 2, 2025. At the time of his appointment, the Board had not determined on which committees Mr. Hennigan would serve. This Form 8-K/A is being filed for the purpose
of providing this information.
On July 22, 2025, the Board appointed Mr. Hennigan to the Audit and Corporate Governance Committees.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
THE CIGNA GROUP
|
|||
|
Date: July 28, 2025
|
By:
|
/s/ Nicole S. Jones
|
|
|
Nicole S. Jones
|
|||
|
Executive Vice President, Chief Administrative Officer and General Counsel
|
|||